title: [Experience with levodopa/carbidopa intestinal gel in the treatment of advanced Parkinson's disease in Hungary].
abstract: In the advanced Parkison's disease (PD) the late complications of levodopa therapy have to be considered: motor and/or non-motor fluctuations with or without disturbing dyskinesias. The non-motor fluctuations often influence the quality of life (QoL) in a much more negative way compared with the motor symptoms. In the treatment of advanced PD there are several device-aided methods - deep brain stimulation, apomorphine pump, levodopa/carbidopa intestinal gel (LCIG) - to improve the symptoms, the QoL, sometimes even in an individual, tailored custom form. The LCIG therapy was introduced in Hungary in 2011. Here we summarize the data of our patients: we have tested almost 60 patients and in 43 cases we have started this treatment. We analyze the duration of illness, levodopa therapy, motor and non-motor fluctuation of patients and present our experiences with the test phase and the chronic LCIG therapy via PEG/PEJ implantation. We paid attention to the surgery and device - depending side effects. Our experiences are similar to the international data. In patients selection ,,the right treatment, to the right patient, in the right time" is of importance.
authors.forename: Helga
authors.initials: H
authors.lastname: Nagy
authors.forename: Annamária
authors.initials: A
authors.lastname: Takáts
authors.forename: Adrián
authors.initials: A
authors.lastname: Tóth
authors.forename: Dániei
authors.initials: D
authors.lastname: Bereczki
authors.forename: Péter
authors.initials: P
authors.lastname: Klivényi
authors.forename: Lívia
authors.initials: L
authors.lastname: Dézsi
authors.forename: György
authors.initials: G
authors.lastname: Dibó
authors.forename: László
authors.initials: L
authors.lastname: Vécsei
authors.forename: Norbert
authors.initials: N
authors.lastname: Kovács
authors.forename: Zsuzsa
authors.initials: Z
authors.lastname: Aschermann
authors.forename: Sámuel
authors.initials: S
authors.lastname: Komoly
authors.forename: Lajos
authors.initials: L
authors.lastname: Varannai
authors.forename: Gyöngyi
authors.initials: G
authors.lastname: Zemlényi
authors.forename: Attila
authors.initials: A
authors.lastname: Valikovics
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002230:Carbidopa / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D005782:Gels; D006801:Humans; D006814:Hungary; D007422:Intestines; D007980:Levodopa / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D018579:Patient Selection; D011788:Quality of Life; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D005782:Gels; D007980:Levodopa; D002230:Carbidopa